GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MIC:REGN-RM) » Definitions » Tariff Resilience Score

Regeneron Pharmaceuticals (MIC:REGN-RM) Tariff Resilience Score : 8/10 (As of Jul. 18, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Regeneron Pharmaceuticals Tariff Resilience Score?

Regeneron Pharmaceuticals has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Regeneron Pharmaceuticals has Regeneron has a strong domestic manufacturing base and limited exposure to international tariffs. Its focus on pharmaceuticals, which are often exempt from tariffs, and strong pricing power enhance its resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Regeneron Pharmaceuticals might have Highly Resilient.

Competitive Comparison of Regeneron Pharmaceuticals's Tariff Resilience Score

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regeneron Pharmaceuticals's Tariff Resilience Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Tariff Resilience Score falls into.


;
;

Regeneron Pharmaceuticals  (MIC:REGN-RM) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Regeneron Pharmaceuticals Tariff Resilience Score Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Tariff Resilience Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MIC:REGN-RM) » Definitions » Tariff Resilience Score
Comparable Companies
ALNY ONC BNTX INSM SMMT RPRX INCY EXEL BMRN MRNA VRTX ASX:CSL XKRX:207940 XBRU:UCB XBRU:ARGX XKRX:068270 HKSE:01801 XKRX:196170 HKSE:02269 OCSE:GMAB
Traded in Other Exchanges
REGN:USA REGN:Mexico 1REGN:Italy 0R2M:UK RGO:Germany RGO:Germany REGN34:Brazil REGN:Austria
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Website
https://www.regeneron.com
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines